cambridge

Cypherpunk Accelerates Zcash Accumulation; Increases Treasury Holdings to 290,062.67 ZEC

CAMBRIDGE, Mass., Dec. 30, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) ("Cypherpunk"), the privacy-focused technology company, today announced a…

1 week ago

U.S. FDA Approves Agios AQVESME (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemiaMarketed under AQVESME brand name…

2 weeks ago

Josh Swihart, ECC CEO, Joins Cypherpunk as Strategic Advisor

CAMBRIDGE, Mass., Dec. 19, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) today announced that Josh Swihart, Chief Executive Officer…

3 weeks ago

Cambridge Mobile Telematics Receives Frost & Sullivan’s 2025 Global Telematics Insurance and Connected Claims Market Leadership Recognition for Excellence in Mobility Ecosystem Innovation

CMT is honored for advancing crash technology and shaping the future of mobility ecosystems through industry-leading telematics, AI-driven insights, and…

3 weeks ago

Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods

BRISBANE, Australia and CAMBRIDGE, Mass., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Australian biotechnology pioneer Vaxxas Pty Ltd, has been granted…

3 weeks ago

Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor

CAMBRIDGE, Mass., Dec. 9, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) today announced that industry pioneer Zooko Wilcox, the founder…

4 weeks ago

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

December 09, 2025 21:50 ET  | Source: Wave Life Sciences USA, Inc. CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) --…

4 weeks ago

Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia

Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm…

4 weeks ago

Eisai Submits New Drug Application for Subcutaneous Formulation of LEQEMBI for the Treatment of Early Alzheimers Disease in Japan

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the…

1 month ago

Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results

CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as Leap Therapeutics, Inc. (Nasdaq:LPTX), a company developing novel…

2 months ago